Growing Biosimilars Business, New Partnerships Support ABT Stock

Zacks2024-12-27

Abbott's ABT diversified business portfolio is well-positioned to drive continued momentum in 2025. The stock carries a Zacks Rank #2 (Buy) currently. Factors Driving ABT Shares Abbott’s Diabetes Care...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2494381844?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-27 21:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2494381844","market":"us","top_or_hot":-1,"title":"Growing Biosimilars Business, New Partnerships Support ABT Stock","media":"Zacks","content":"<div>\n<p>Abbott's ABT diversified business portfolio is well-positioned to drive continued momentum in 2025. The stock carries a Zacks Rank #2 (Buy) currently.\nFactors Driving ABT Shares\nAbbott’s Diabetes Care...</p>\n\n<a href=\"https://finance.yahoo.com/news/growing-biosimilars-business-partnerships-support-134600591.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance_au","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Growing Biosimilars Business, New Partnerships Support ABT Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrowing Biosimilars Business, New Partnerships Support ABT Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-27 21:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/growing-biosimilars-business-partnerships-support-134600591.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Abbott's ABT diversified business portfolio is well-positioned to drive continued momentum in 2025. The stock carries a Zacks Rank #2 (Buy) currently.\nFactors Driving ABT Shares\nAbbott’s Diabetes Care...</p>\n\n<a href=\"https://finance.yahoo.com/news/growing-biosimilars-business-partnerships-support-134600591.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RMD","symbol_name":"瑞思迈","start_time":0,"source_url":"https://finance.yahoo.com/news/growing-biosimilars-business-partnerships-support-134600591.html","article_id":"2494381844","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2494381844","pubTimestamp":1735307160,"columns":[],"sourceInfo":{"source_id":"yahoofinance_au","name":"Yahoo Finance AU"},"weMediaInfo":null,"summary":"Abbott's ABT diversified business portfolio is well-positioned to drive continued momentum in 2025. The stock carries a Zacks Rank #2  currently.Abbott’s Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre. In a relatively short span, FreeStyle Libre has achieved global leadership among continuous glucose monitoring  systems for both Type 1 and Type 2 users.In the third quarter, Diabetes Care sales of CGM exceeded $1.6 billion and grew 21%. In August, the company announced that it had entered into a unique global partnership with Medtronic to connect Abbott's FreeStyle Libre CGM sensor with Medtronic’s automated insulin delivery systems.The challenging macroeconomic scenario in the form of the ongoing complex geo-political situation globally, specifically where Abbott operates, is driving a higher-than-anticipated increase in raw materials and freight expenses. These could also result in ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"RMD":"瑞思迈","LU1721429741.USD":"BNP PARIBAS SMART FOOD \"CRH\" (USD) INC","ABT.AU":"Abundant Produce","LU0234572021.USD":"高盛美国核心股票组合Acc","BK7501":"新冠治疗股","PEN.AU":"PENINSULA ENERGY LTD","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK4561":"索罗斯持仓","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK4504":"桥水持仓","BK4581":"高盛持仓","HAE":"美国血液技术","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","RMD.AU":"Resmed DRC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","BK4548":"巴美列捷福持仓","BK4588":"碎股","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","LU1150488135.SGD":"First Eagle Amundi Income Builder AHS-MD SGD-H","EPD":"Enterprise Products Partners L.P","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4144":"石油与天然气的储存和运输","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4592":"伊斯兰概念","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","ABT":"雅培","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BK7083":"煤与消费用燃料","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","BK4566":"资本集团","BK4568":"美国抗疫概念","EPD.AU":"Empired Ltd","BK4082":"医疗保健设备","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","PEN":"Penumbra Inc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC"},"translate_title":"不断增长的生物仿制药业务，新的合作伙伴关系支持ABT股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABT.AU":1,"EPD":1,"EPD.AU":1,"HAE":1,"PEN":1,"PEN.AU":1,"RMD":1,"ABT":1,"RMD.AU":0.9},"content_text":"Abbott's ABT diversified business portfolio is well-positioned to drive continued momentum in 2025. The stock carries a Zacks Rank #2 (Buy) currently.\nFactors Driving ABT Shares\nAbbott’s Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre. In a relatively short span, FreeStyle Libre has achieved global leadership among continuous glucose monitoring (CGM) systems for both Type 1 and Type 2 users.\nIn the third quarter, Diabetes Care sales of CGM exceeded $1.6 billion and grew 21%. In August, the company announced that it had entered into a unique global partnership with Medtronic to connect Abbott's FreeStyle Libre CGM sensor with Medtronic’s automated insulin delivery systems.\nAbbott continues to expand its Diagnostics business foothold (consisting of 22.6% of the total revenues in the third quarter of 2024). On a global scale, Abbott currently holds a prominent position in point-of-care testing, with a portfolio focused on four key areas — Infectious Disease, Cardiometabolic & Informatics, Toxicology and Consumer Diagnostics. In rapid and point-of-care diagnostics businesses, the company is successfully expanding its test menus and is also capitalizing on the growing demand for respiratory tests that can be performed at home or in more traditional healthcare settings.\nWithin Abbott’s Established Pharmaceuticals Division (EPD) business, the company is also strategically progressing with its advancement in biosimilars. Abbott, leveraging on its leading presence in emerging markets, is enjoying a unique opportunity to scale a licensing model that is capital-efficient and can bring access to these life-changing medicines to the emerging market population. The company agreed to commercialize several biosimilars in the areas of oncology and women’s health in 2023. The first round of commercialization is on track for 2025. The company is highly optimistic about this initiative considering the fact that biosimilars represent the highest growth segment in the branded generic pharmaceutical market.\n\nAbbott Laboratories Price\n\nAbbott Laboratories price | Abbott Laboratories Quote\n\nOver the past three months, shares of ABT have gained 2.6% against the industry’s 2.2% decline. The company’s consistent efforts to expand in high-growth areas, as well as its array of new product launches are expected to help the stock to continue with its uptrend in the coming days.\nConcerns Remain for Abbott\nThe challenging macroeconomic scenario in the form of the ongoing complex geo-political situation globally, specifically where Abbott operates, is driving a higher-than-anticipated increase in raw materials and freight expenses. These could also result in broader economic impacts and security concerns, affecting the company’s business in the upcoming months. Industrywide, it has been seen that the deteriorating global economic environment is reducing demand for several MedTech products, resulting in lower sales and lower product prices while increasing the cost of goods and operating expenses of the businesses of the MedTech companies.In the third quarter, Abbott incurred a 2.1% increase in the cost of products sold (excluding amortization expense). Selling, general and administration expenses were up 6.3% year over year.\nForeign exchange is a major headwind for Abbott due to a considerable percentage of its revenues coming from outside the United States. The strengthening of the euro and some other developed market currencies has constantly been hampering the company’s performance in the international markets. In the third quarter of 2024, foreign exchange had an unfavorable year-over-year impact of 2.5% on sales.\nOther Key Picks\nSome other top-ranked stocks in the broader medical space are Penumbra PEN, Haemonetics HAE and ResMed RMD, each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nPenumbra’s shares have risen 10.5% in the past year. Estimates for the company’s 2024 earnings per share (EPS) have jumped 0.7% to $2.81 in the past 30 days. PEN’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 10.54%. In the last reported quarter, it posted an earnings surprise of 23.19%.\nEstimates for Haemonetics’ fiscal 2025 EPS have remained constant at $4.59 in the past 30 days. Shares of the company have lost 3.6% in the past year against the industry’s growth of 17.3%. HAE’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.82%. In the last reported quarter, it delivered an earnings surprise of 2.75%.\nEstimates for ResMed’s fiscal 2025 EPS have increased 2.5% to $1.61 in the past 30 days. Shares of the company have surged 113.5% in the past year compared with the industry’s 17.3% growth. RMD’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 25.47%. In the last reported quarter, it delivered an earnings surprise of 52.17%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAbbott Laboratories (ABT) : Free Stock Analysis Report\nResMed Inc. (RMD) : Free Stock Analysis Report\nHaemonetics Corporation (HAE) : Free Stock Analysis Report\nPenumbra, Inc. (PEN) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2494381844"}